Targeted  ||| S:0 E:9 ||| JJ
therapy  ||| S:9 E:17 ||| NN
for  ||| S:17 E:21 ||| IN
hereditary  ||| S:21 E:32 ||| JJ
cancer  ||| S:32 E:39 ||| NN
syndromes ||| S:39 E:48 ||| NNS
:  ||| S:48 E:50 ||| :
hereditary  ||| S:50 E:61 ||| JJ
breast  ||| S:61 E:68 ||| NN
and  ||| S:68 E:72 ||| CC
ovarian  ||| S:72 E:80 ||| JJ
cancer  ||| S:80 E:87 ||| NN
syndrome ||| S:87 E:95 ||| NN
,  ||| S:95 E:97 ||| ,
Lynch  ||| S:97 E:103 ||| NNP
syndrome ||| S:103 E:111 ||| NN
,  ||| S:111 E:113 ||| ,
familial  ||| S:113 E:122 ||| FW
adenomatous  ||| S:122 E:134 ||| FW
polyposis ||| S:134 E:143 ||| FW
,  ||| S:143 E:145 ||| ,
and  ||| S:145 E:149 ||| CC
Li-Fraumeni  ||| S:149 E:161 ||| JJ
syndrome  ||| S:161 E:170 ||| NN
Cancer  ||| S:170 E:177 ||| NNP
genetics  ||| S:177 E:186 ||| NN
has  ||| S:186 E:190 ||| VBZ
rapidly  ||| S:190 E:198 ||| RB
evolved  ||| S:198 E:206 ||| VBN
in  ||| S:206 E:209 ||| IN
the  ||| S:209 E:213 ||| DT
last  ||| S:213 E:218 ||| JJ
two  ||| S:218 E:222 ||| CD
decades ||| S:222 E:229 ||| NNS
.  ||| S:229 E:231 ||| .
Understanding  ||| S:231 E:245 ||| NN
and  ||| S:245 E:249 ||| CC
exploring  ||| S:249 E:259 ||| VBG
the  ||| S:259 E:263 ||| DT
several  ||| S:263 E:271 ||| JJ
genetic  ||| S:271 E:279 ||| JJ
pathways  ||| S:279 E:288 ||| NN
in  ||| S:288 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
cancer  ||| S:295 E:302 ||| NN
cell  ||| S:302 E:307 ||| NN
is  ||| S:307 E:310 ||| VBZ
the  ||| S:310 E:314 ||| DT
foundation  ||| S:314 E:325 ||| NN
of  ||| S:325 E:328 ||| IN
targeted  ||| S:328 E:337 ||| JJ
therapy ||| S:337 E:344 ||| NN
.  ||| S:344 E:346 ||| .
Several  ||| S:346 E:354 ||| JJ
genomic  ||| S:354 E:362 ||| JJ
aberrations  ||| S:362 E:374 ||| NNS
have  ||| S:374 E:379 ||| VBP
been  ||| S:379 E:384 ||| VBN
identified  ||| S:384 E:395 ||| VBN
and  ||| S:395 E:399 ||| CC
their  ||| S:399 E:405 ||| PRP$
role  ||| S:405 E:410 ||| NN
in  ||| S:410 E:413 ||| IN
carcinogenesis  ||| S:413 E:428 ||| NN
is  ||| S:428 E:431 ||| VBZ
being  ||| S:431 E:437 ||| VBG
explored ||| S:437 E:445 ||| NNS
.  ||| S:445 E:447 ||| .
In  ||| S:447 E:450 ||| IN
contrast  ||| S:450 E:459 ||| NN
to  ||| S:459 E:462 ||| TO
most  ||| S:462 E:467 ||| JJS
cancers  ||| S:467 E:475 ||| NNS
where  ||| S:475 E:481 ||| WRB
these  ||| S:481 E:487 ||| DT
mutations  ||| S:487 E:497 ||| NNS
are  ||| S:497 E:501 ||| VBP
acquired ||| S:501 E:509 ||| VBN
,  ||| S:509 E:511 ||| ,
patients  ||| S:511 E:520 ||| NNS
with  ||| S:520 E:525 ||| IN
hereditary  ||| S:525 E:536 ||| JJ
cancer  ||| S:536 E:543 ||| NN
syndromes  ||| S:543 E:553 ||| NNS
have  ||| S:553 E:558 ||| VBP
inherited  ||| S:558 E:568 ||| VBN
genomic  ||| S:568 E:576 ||| JJ
aberrations ||| S:576 E:587 ||| NN
.  ||| S:587 E:589 ||| .
The  ||| S:589 E:593 ||| DT
understanding  ||| S:593 E:607 ||| NN
of  ||| S:607 E:610 ||| IN
the  ||| S:610 E:614 ||| DT
molecular  ||| S:614 E:624 ||| JJ
pathobiology  ||| S:624 E:637 ||| NN
in  ||| S:637 E:640 ||| IN
hereditary  ||| S:640 E:651 ||| JJ
cancer  ||| S:651 E:658 ||| NN
syndromes  ||| S:658 E:668 ||| NN
has  ||| S:668 E:672 ||| VBZ
advanced  ||| S:672 E:681 ||| VBN
dramatically ||| S:681 E:693 ||| RB
.  ||| S:693 E:695 ||| .
In  ||| S:695 E:698 ||| IN
addition ||| S:698 E:706 ||| NN
,  ||| S:706 E:708 ||| ,
many  ||| S:708 E:713 ||| JJ
molecularly  ||| S:713 E:725 ||| NNS
targeted  ||| S:725 E:734 ||| VBN
therapies  ||| S:734 E:744 ||| NNS
have  ||| S:744 E:749 ||| VBP
been  ||| S:749 E:754 ||| VBN
developed  ||| S:754 E:764 ||| VBN
that  ||| S:764 E:769 ||| WDT
could  ||| S:769 E:775 ||| MD
have  ||| S:775 E:780 ||| VB
potential  ||| S:780 E:790 ||| JJ
roles  ||| S:790 E:796 ||| NNS
in  ||| S:796 E:799 ||| IN
the  ||| S:799 E:803 ||| DT
treatment  ||| S:803 E:813 ||| NN
of  ||| S:813 E:816 ||| IN
patients  ||| S:816 E:825 ||| NNS
with  ||| S:825 E:830 ||| IN
hereditary  ||| S:830 E:841 ||| JJ
cancer  ||| S:841 E:848 ||| NN
syndromes ||| S:848 E:857 ||| NN
.  ||| S:857 E:859 ||| .
In  ||| S:859 E:862 ||| IN
this  ||| S:862 E:867 ||| DT
review ||| S:867 E:873 ||| NN
,  ||| S:873 E:875 ||| ,
we  ||| S:875 E:878 ||| PRP
outline  ||| S:878 E:886 ||| VB
the  ||| S:886 E:890 ||| DT
presentation ||| S:890 E:902 ||| NN
,  ||| S:902 E:904 ||| ,
molecular  ||| S:904 E:914 ||| JJ
biology ||| S:914 E:921 ||| NN
,  ||| S:921 E:923 ||| ,
and  ||| S:923 E:927 ||| CC
possible  ||| S:927 E:936 ||| JJ
targeted  ||| S:936 E:945 ||| JJ
therapies  ||| S:945 E:955 ||| NNS
for  ||| S:955 E:959 ||| IN
two  ||| S:959 E:963 ||| CD
of  ||| S:963 E:966 ||| IN
the  ||| S:966 E:970 ||| DT
most  ||| S:970 E:975 ||| RBS
widely  ||| S:975 E:982 ||| RB
recognized  ||| S:982 E:993 ||| VBN
hereditary  ||| S:993 E:1004 ||| JJ
cancer  ||| S:1004 E:1011 ||| NN
syndromes  ||| S:1011 E:1021 ||| NNS
--  ||| S:1021 E:1024 ||| :
hereditary  ||| S:1024 E:1035 ||| JJ
breast  ||| S:1035 E:1042 ||| NN
and  ||| S:1042 E:1046 ||| CC
ovarian  ||| S:1046 E:1054 ||| JJ
cancer  ||| S:1054 E:1061 ||| NN
syndrome  ||| S:1061 E:1070 ||| NN
and  ||| S:1070 E:1074 ||| CC
hereditary  ||| S:1074 E:1085 ||| JJ
non-polyposis  ||| S:1085 E:1099 ||| JJ
colorectal  ||| S:1099 E:1110 ||| JJ
cancer  ||| S:1110 E:1117 ||| NN
syndrome  ||| S:1117 E:1126 ||| NN
( ||| S:1126 E:1127 ||| -LRB-
Lynch  ||| S:1127 E:1133 ||| NNP
syndrome ||| S:1133 E:1141 ||| NN
) ||| S:1141 E:1142 ||| -RRB-
.  ||| S:1142 E:1144 ||| .
We  ||| S:1144 E:1147 ||| PRP
will  ||| S:1147 E:1152 ||| MD
also  ||| S:1152 E:1157 ||| RB
discuss  ||| S:1157 E:1165 ||| VB
other  ||| S:1165 E:1171 ||| JJ
syndromes  ||| S:1171 E:1181 ||| JJ
such  ||| S:1181 E:1186 ||| JJ
as  ||| S:1186 E:1189 ||| IN
familial  ||| S:1189 E:1198 ||| JJ
adenomatous  ||| S:1198 E:1210 ||| JJ
polyposis  ||| S:1210 E:1220 ||| NN
and  ||| S:1220 E:1224 ||| CC
Li-Fraumeni  ||| S:1224 E:1236 ||| JJ
syndrome  ||| S:1236 E:1245 ||| NN
( ||| S:1245 E:1246 ||| -LRB-
TP53 ||| S:1246 E:1250 ||| NNP
) ||| S:1250 E:1251 ||| -RRB-
.  ||| S:1251 E:1253 ||| .
